Efficacy and safety of sequential moxifloxacin IV / PO compared to levofloxacin IV plus ceftriaxone IV followed by PO levofloxacin, in the treatment of patients with community-acquired pneumonia.
Not Applicable
Completed
- Conditions
- -J15J15
- Registration Number
- PER-094-03
- Lead Sponsor
- BAYER S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients 18 years of age or older.
All the signs and symptoms of pneumonia.
Fine Score> 71
Informed written consent obtained from the patient or legal representative.
Exclusion Criteria
Known hypersensitivity to fluoroquinolones, or other quinolones, and / or to beta-lactams, and / or to macrolide antibiotic medications.
Female patients who are pregnant or breastfeeding.
Antecedents of disease / tendon alteration related to treatment with fluroquinolones.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method